| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Varenicline | FAERS: 3 | US FAERS | |
| 2 | Alendronate | FAERS: 2 | US FAERS | |
| 3 | Deferasirox | FAERS: 2 | US FAERS | |
| 4 | Aspirin-oxycodone hydrochloride-oxycodone terephthalate combination | FAERS: 1 | US FAERS | |
| 5 | Desvenlafaxine Succinate | FAERS: 1 | US FAERS | |
| 6 | Finasteride | FAERS: 1 | US FAERS | |
| 7 | Fluoxetine | FAERS: 1 | US FAERS | |
| 8 | Lamotrigine | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 9 | NuvaRing | FAERS: 1 | US FAERS | |
| 10 | Pamidronate | FAERS: 1 | US FAERS | |
| 11 | Raloxifene Hydrochloride | FAERS: 1 | US FAERS | |
| 12 | Sildenafil Citrate | FAERS: 1 | US FAERS | |
| 13 | Zoledronic Acid | FAERS: 1 | US FAERS | |
| 14 | rofecoxib | FAERS: 1 | US FAERS |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120295
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.